Literature DB >> 29633185

Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression.

X Lin1, Y Wang2.   

Abstract

PURPOSE: Her-2 is an epidermal growth factor receptor expressed in some prostate cancers (PC) associated with outgrowth of the tumor. Dysregulation of some microRNAs is involved in the regulation of PC pathogenesis, whereas the role of miR-4319 in PC is unknown and addressed in the current study.
METHODS: The levels of miR-4319 in PC tissues were determined by RT-qPCR and their association with patient survival was studied by Kaplan-Meier analysis. Targeted genes for miR-4319 were predicted by a bioinformatics algorithm and confirmed by a dual-luciferase reporter assay. Growth of cells of overexpression or inhibition of miR-4319 or Her-2 was analyzed by an MTT assay. Cell survival in response to a chemotherapeutic drug, estramustine (EM), was analyzed by CCK-8 assay. Cell apoptosis was evaluated by TUNEL assay and Western blotting for apoptosis-associated proteins.
RESULTS: MiR-4319 levels were decreased in PC specimens, compared to corresponding normal prostate tissue. Lower levels of miR-4319 were correlated with poorer overall patients' survival. In vitro, the cell survival mediated with Her-2 against chemotherapy was inhibited by overexpression of miR-4319 and was enhanced by depletion of miR-4319. Depletion of miR-4319 in primary prostate epithelial cells increased Her-2-dependent cell growth, while re-expression of miR-4319 in PC cells inhibited Her-2-dependent cell growth and Her-2-dependent resistance to EM-induced apoptosis.
CONCLUSION: The growth and chemo-resistance of PC cells may be suppressed via re-expression of miR-4319 that inhibits Her-2 signaling.

Entities:  

Keywords:  Chemotherapy; Growth; Her-2; Prostate cancer (PC); miR-4319

Mesh:

Substances:

Year:  2018        PMID: 29633185     DOI: 10.1007/s12094-018-1871-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  25 in total

1.  A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence.

Authors:  Joshua J Forman; Aster Legesse-Miller; Hilary A Coller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

2.  MicroRNA regulation of stem cell fate.

Authors:  Qintong Li; Richard I Gregory
Journal:  Cell Stem Cell       Date:  2008-03-06       Impact factor: 24.633

3.  MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.

Authors:  Seong O Suh; Yi Chen; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Varahram Shahryari; Jan Liu; Z Laura Tabatabai; Sanjay Kakar; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-02-23       Impact factor: 4.944

4.  Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence.

Authors:  Nigel P Murray; Eduardo Reyes; Cynthia Fuentealba; Omar Jacob; Nelson Orellana
Journal:  Asian Pac J Cancer Prev       Date:  2015

5.  Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Authors:  A D Seidman; H I Scher; D Petrylak; D D Dershaw; T Curley
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

6.  MicroRNA regulation of cell lineages in mouse and human embryonic stem cells.

Authors:  Kathryn N Ivey; Alecia Muth; Joshua Arnold; Frank W King; Ru-Fang Yeh; Jason E Fish; Edward C Hsiao; Robert J Schwartz; Bruce R Conklin; Harold S Bernstein; Deepak Srivastava
Journal:  Cell Stem Cell       Date:  2008-03-06       Impact factor: 24.633

Review 7.  Targeting HER 2 and angiogenesis in gastric cancer.

Authors:  G Jomrich; S F Schoppmann
Journal:  Expert Rev Anticancer Ther       Date:  2015-12-05       Impact factor: 4.512

8.  Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.

Authors:  Carmela Ricciardelli; Michael W Jackson; Catherine S Choong; Jürgen Stahl; Villis R Marshall; David J Horsfall; Wayne D Tilley
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

9.  SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Angela Minervini; Giorgina Specchia
Journal:  J Hematol Oncol       Date:  2012-08-08       Impact factor: 17.388

Review 10.  Prostate cancer stroma: an important factor in cancer growth and progression.

Authors:  Božo Krušlin; Monika Ulamec; Davor Tomas
Journal:  Bosn J Basic Med Sci       Date:  2015-05-13       Impact factor: 3.363

View more
  10 in total

1.  MiR-4319 suppresses colorectal cancer progression by targeting ABTB1.

Authors:  Longchang Huang; Ye Zhang; Zengyao Li; Xiaoqian Zhao; Zhong Xi; Hang Chen; Haoze Shi; Taojian Xin; Renhui Shen; Tong Wang
Journal:  United European Gastroenterol J       Date:  2019-03-06       Impact factor: 4.623

Review 2.  Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions.

Authors:  Eduardo de Paula Nascente; Renée Laufer Amorim; Carlos Eduardo Fonseca-Alves; Veridiana Maria Brianezi Dignani de Moura
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

Review 3.  Alkylating anticancer agents and their relations to microRNAs.

Authors:  Bernhard Biersack
Journal:  Cancer Drug Resist       Date:  2019-03-19

4.  SEMA4D under the posttranscriptional regulation of HuR and miR-4319 boosts cancer progression in esophageal squamous cell carcinoma.

Authors:  Yan Wang; Hongli Zhao; Weiwei Zhi
Journal:  Cancer Biol Ther       Date:  2019-10-25       Impact factor: 4.742

5.  Circular RNA ATXN7 promotes the development of gastric cancer through sponging miR-4319 and regulating ENTPD4.

Authors:  Zhen Zhang; Honglei Wu; Zhaosheng Chen; Guangchun Li; Bin Liu
Journal:  Cancer Cell Int       Date:  2020-01-23       Impact factor: 5.722

6.  MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1.

Authors:  Shaoshan Han; Yu Shi; Liankang Sun; Zhikui Liu; Tao Song; Qingguang Liu
Journal:  Int J Biol Sci       Date:  2019-11-15       Impact factor: 6.580

7.  DLG1-AS1 is activated by MYC and drives the proliferation and migration of hepatocellular carcinoma cells through miR-497-5p/SSRP1 axis.

Authors:  Jie Min; Dayong Jin; Feng Zhang; Yanxia Kang; Yuhong Qi; Pang Du
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

8.  CTCF-silenced miR-137 contributes to EMT and radioresistance in esophageal squamous cell carcinoma.

Authors:  Shuwen Xu; Xiaofeng Li; Longfei Li; Yufeng Wang; Chong Geng; Feng Guo; Tao Zhang; Aonan Du; Zhiwei Lu; Hua Hui; Qiang Wang
Journal:  Cancer Cell Int       Date:  2021-03-08       Impact factor: 5.722

9.  miR-4319 inhibited retinoblastoma cells proliferation, migration, invasion and EMT progress via suppressing CD147 mediated MMPs expression.

Authors:  Zhiqing Wu; Ling Chen; Chengyue Zhang; Yanfang Liu
Journal:  J Mol Histol       Date:  2021-01-20       Impact factor: 2.611

10.  Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Rama Jayaraj; Greg Raymond; Sunil Krishnan; Katherine S Tzou; Siddhartha Baxi; M Ravishankar Ram; Suresh Kumar Govind; Harish C Chandramoorthy; Faisal N Abu-Khzam; Peter Shaw
Journal:  Cancers (Basel)       Date:  2020-05-09       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.